Current Headlines

  1. Puma Biotechnology Updates Timeline For Filing New Drug Application
    12/2/2014

    Puma Biotechnology, Inc., a development stage biopharmaceutical company, recently provided an update on the timeline for filing its New Drug Application (NDA) for the approval of PB272 (neratinib) in the extended adjuvant treatment of HER2-positive early stage breast cancer

  2. BASi’s Culex L Large Animal Sampling System Combines An Ideal Model With An Ideal Tool For Improved Drug Development Research
    12/2/2014

    For nearly 15 years, the Culex Automated Blood Sampling systems have allowed researchers to collect better data from non-stressed subjects

  3. BioVersys And Enamine Announce Extension Of Drug Discovery Collaboration To Address Multidrug-Resistant Bacterial Infections
    12/2/2014

    Enamine Ltd. and BioVersys AG announced recently the extension of their drug discovery collaboration for the 4th consecutive year

  4. Otsuka Pharmaceutical To Acquire Avanir Pharmaceuticals
    12/2/2014

    Otsuka Pharmaceutical Co., Ltd. is pleased to announce an agreement with Avanir Pharmaceuticals, Inc. (“Avanir”) in which Otsuka America, Inc., a US subsidiary, acquires Avanir for USD 3.5 billion in an all-cash tender offer

  5. Researchers Discover Potential New Treatment Method For ALS
    12/2/2014

    A team of scientists at Thomas Jefferson University reported their discovery of a new approach to help enhance the efficacy of drugs that target Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease.

  6. Acetylon’s Selective HDAC Inhibitors To Be Featured In Multiple Presentations Of Positive Clinical And Preclinical Data At The 56th ASH Annual Meeting And Exposition
    12/1/2014

    Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, recently announced that ricolinostat, the Company’s lead selective HDAC6 inhibitor, and selective HDAC1/2 inhibitors will be featured in one oral presentation and five posters at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6-9, 2014, in San Francisco, CA

  7. Southern Research Continues 24 Years Of HIV Work With New NIH Contract
    12/1/2014

    Southern Research has been awarded a $24 million, seven-year contract with the Division of AIDS, part of the National Institutes of Health, to provide drug discovery and development services to develop products that have the potential to become drugs for the treatment and prevention of HIV

  8. Sanford-Burnham Scientist Wins GlaxoSmithKline Drug Discovery Challenge To Develop New Therapy For High Blood Pressure
    12/1/2014

    Sanford-Burnham Medical Research Institute at Lake Nona (Sanford-Burnham) and Mayo Clinic recently announced that a joint team of scientists has been selected as a winner of GlaxoSmithKline (GSK)’s 2014 Discovery Fast Track Challenge

  9. Sevion Therapeutics Announces Chimerasome Research Agreement
    11/24/2014

    Sevion Therapeutics, a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, recently announced that it has entered into a research agreement with Avidity NanoMedicines LLC related to the use of Sevion’s chimerasome technology for delivery of nucleic acids

  10. AstraZeneca Announces Plans To Expand Its Frederick, Maryland Biologics Manufacturing Center
    11/21/2014

    AstraZeneca recently announced plans to expand its biologics manufacturing center in Frederick, Md. The more than $200M project will increase production capacity at the facility to support AstraZeneca’s maturing pipeline, and will help position the company to keep pace with a growing demand for the development and use of biologics, which currently represent nearly 50% of AstraZeneca’s overall pipeline

Newsletter Signup
Newsletter Signup
Get the latest industry news, insights, and analysis delivered to your inbox.
Join your peers
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.